169 related articles for article (PubMed ID: 22520731)
1. The treatment of glioblastoma multiforme through activation of microglia and TRAIL induced by rAAV2-mediated IL-12 in a syngeneic rat model.
Chiu TL; Wang MJ; Su CC
J Biomed Sci; 2012 Apr; 19(1):45. PubMed ID: 22520731
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anti-glioblastoma activity of microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in vitro.
Chiu TL; Peng CW; Wang MJ
Oncol Rep; 2011 May; 25(5):1373-80. PubMed ID: 21399879
[TBL] [Abstract][Full Text] [Related]
3. AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells.
Chiu TL; Lin SZ; Hsieh WH; Peng CW
Int J Oncol; 2009 Dec; 35(6):1361-7. PubMed ID: 19885559
[TBL] [Abstract][Full Text] [Related]
4. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
[TBL] [Abstract][Full Text] [Related]
5. Enriched Environment Cues Suggest a New Strategy to Counteract Glioma: Engineered rAAV2-IL-15 Microglia Modulate the Tumor Microenvironment.
Mormino A; Bernardini G; Cocozza G; Corbi N; Passananti C; Santoni A; Limatola C; Garofalo S
Front Immunol; 2021; 12():730128. PubMed ID: 34552593
[TBL] [Abstract][Full Text] [Related]
6. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
Jiang X; Fitch S; Wang C; Wilson C; Li J; Grant GA; Yang F
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13857-13862. PubMed ID: 27849590
[TBL] [Abstract][Full Text] [Related]
8. Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.
Ru Q; Li W; Wang X; Zhang S; Chen L; Zhang Y; Ge Y; Zu Y; Liu Y; Zheng D
Cancer Gene Ther; 2017 Jun; 24(6):251-258. PubMed ID: 28429751
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro.
Chen J; Sun X; Yang W; Jiang G; Li X
Tumour Biol; 2010 Dec; 31(6):613-22. PubMed ID: 20623264
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice.
Shi J; Zheng D; Liu Y; Sham MH; Tam P; Farzaneh F; Xu R
Cancer Res; 2005 Mar; 65(5):1687-92. PubMed ID: 15753363
[TBL] [Abstract][Full Text] [Related]
11. MCP-1 and MIP-3α Secreted from Necrotic Cell-Treated Glioblastoma Cells Promote Migration/Infiltration of Microglia.
Jung Y; Ahn SH; Park H; Park SH; Choi K; Choi C; Kang JL; Choi YH
Cell Physiol Biochem; 2018; 48(3):1332-1346. PubMed ID: 30048972
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma.
Thorsen F; Afione S; Huszthy PC; Tysnes BB; Svendsen A; Bjerkvig R; Kotin RM; Lønning PE; Hoover F
J Gene Med; 2006 Sep; 8(9):1131-40. PubMed ID: 16810631
[TBL] [Abstract][Full Text] [Related]
13. Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model.
GuhaSarkar D; Neiswender J; Su Q; Gao G; Sena-Esteves M
Mol Oncol; 2017 Feb; 11(2):180-193. PubMed ID: 28098415
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.
Eramo A; Pallini R; Lotti F; Sette G; Patti M; Bartucci M; Ricci-Vitiani L; Signore M; Stassi G; Larocca LM; Crinò L; Peschle C; De Maria R
Cancer Res; 2005 Dec; 65(24):11469-77. PubMed ID: 16357155
[TBL] [Abstract][Full Text] [Related]
15. Semliki Forest virus-mediated gene therapy of the RG2 rat glioma.
Roche FP; Sheahan BJ; O'Mara SM; Atkins GJ
Neuropathol Appl Neurobiol; 2010 Dec; 36(7):648-60. PubMed ID: 20649937
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 transduction of a rat T9 glioma clone results in attenuated tumorigenicity and induces glioma immunity in Fischer F344 rats.
Graf MR; Merchant RE
J Neurooncol; 1999; 45(3):209-18. PubMed ID: 10845391
[TBL] [Abstract][Full Text] [Related]
17. Widespread dispersion of adeno-associated virus serotype 1 and adeno-associated virus serotype 6 vectors in the rat central nervous system and in human glioblastoma multiforme xenografts.
Huszthy PC; Svendsen A; Wilson JM; Kotin RM; Lønning PE; Bjerkvig R; Hoover F
Hum Gene Ther; 2005 Mar; 16(3):381-92. PubMed ID: 15812233
[TBL] [Abstract][Full Text] [Related]
18. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
[TBL] [Abstract][Full Text] [Related]
19. Epirubicin potentiates recombinant adeno-associated virus type 2/5-mediated TRAIL expression in fibroblast-like synoviocytes and augments the antiarthritic effects of rAAV2/5-TRAIL.
Shi J; Diao Z; Zhou J; Zhu J; Yuan H; You X; Liu Y; Zheng D
Arthritis Rheum; 2012 May; 64(5):1345-54. PubMed ID: 22131069
[TBL] [Abstract][Full Text] [Related]
20. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
